|会社名||Cellectis SA （セレクティス）|
|分野（sector）||Health Care ヘルスケア|
|産業（industry）||Biotechnology: Biological Products (No Diagnostic Substances)|
|業種||バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care）|
|概要||事業概要 Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS) used for gene excision correction or replacement. The Company also offers rational inverse genetics and targeting recombination tools. Cellectis SA markets its technologies mainly for use in the research field in pharmaceutical drug discovery programs in the agronomics bioproduction and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States among others. セレクティスは、フランスのゲノム工学会社。独自のコア技術を採用し、免疫腫瘍学の分野で製品を開発する。同社の製品には、B細胞悪性腫瘍などのCD19を有する細胞を標的とし殺傷することのできるT細胞製品のUCART19がある。また、製品の候補には、UCART123、UCARTCS1、UCART38などがある。|
|本社所在地||8 rue de la Croix Jarry Paris 75013 FRA|
|代表者氏名||Andre Choulika アンドレ・チュリカ|
|代表者役職名||Chairman of the Board Chief Executive Officer Member of the Executive Board|
|市場名||NASDAQ National Market System|
|決算概要||決算概要 BRIEF: For the six months ended 30 June 2018 Cellectis SA (ADR) revenues decreased 15% to $16.4M. Net loss decreased 30% to $32.4M. Revenues reflect Revenues decrease of 16% to $11.1M Other income decrease of 12% to $5.3M. Lower net loss reflects Financial expenses decrease of 74% to $3M (expense) Financial Income increase from $4.7M to $13M (income) Research and development expenses decrease of 5% to $36.4M (expense).|
Cellectis SA (CLLS) Q1 2023 Earnings Call Transcript 2023/05/05 17:15:07 Seeking Alpha
Cellectis SA (NASDAQ:NASDAQ:CLLS) Q1 2023 Earnings Conference Call May 5, 2023 8:00 AM ETCompany ParticipantsArthur Stril - Chief Business OfficerAndre Choulika - Co-Founder, CEO &…
Cellectis Non-GAAP EPS of -$0.55 misses by $0.13, revenue of $3.56M misses by $2.54M 2023/05/04 21:33:59 Seeking Alpha
Cellectis press release (CLLS): Q1 Non-GAAP EPS of -$0.55 misses by $0.13.Revenue of $3.56M (-7.0% Y/Y) misses by $2.54M.
Recap: Cellectis Q1 Earnings 2023/05/04 20:51:18 Benzinga
Cellectis (NASDAQ: CLLS ) reported its Q1 earnings results on Thursday, May 4, 2023 at 04:30 PM. Here''s what investors need to know about the announcement. Earnings Cellectis missed estimated earnings by 14.58%, reporting an EPS … Full story available on Benzinga.com
Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab 2023/04/24 20:30:00 GlobeNewswire
NEW YORK, April 24, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced it has implemented the use of alemtuzumab as a Cellectis Investigational Medicinal Product (IMP), coded as CLLS52, as part of the lymphodepletion regimen for UCART22 in the BALLI-01 clinical trial in relapsed/refractory B-cell ALL, for UCART123 in the AMELI-01 clinical trial in relapsed/refractory AML, and for UCART20x22 in the NatHaLi-01 clinical trial in relapsed/refractory B-cell NHL.
Cellectis Presents Preclinical Data on TALEN-edited MUC1 CAR T-cells 2023/04/17 09:33:01 Investing.com
A Preview Of Cellectis''s Earnings 2023/03/07 14:01:52 Benzinga
Cellectis (NASDAQ: CLLS ) is set to give its latest quarterly earnings report on Wednesday, 2023-03-08. Here''s what investors need to know before the announcement. Analysts estimate that Cellectis will report an earnings per share (EPS) of $-0.71. Cellectis bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the … Full story available on Benzinga.com
Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update 2023/03/06 21:30:00 GlobeNewswire
NEW YORK, 06 mars 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company for which Cellectis owns 49.1% (as of December 31, 2022) of its issued and outstanding common stock, today announced operating and financial results for its fourth quarter ended December 31, 2022. The contents of Calyxt’s announcement are included below:
Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023 2023/03/01 21:30:00 GlobeNewswire
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and year-end 2022 ending December 31 st , 2022, on Wednesday, March 8, 2023, after the close of the US market.
Cellectis Announces Closing of Global Offering and Exercise 2023/02/08 00:01:00 businessfortnight.com
NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) — Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to […] The post Cellectis Announces Closing of Global Offering and Exercise appeared first on Businessfortnight .
Cellectis shares dip on pricing follow-on offering at $2.50/ADS 2023/02/03 10:46:11 Seeking Alpha
Cellectis S.A. (CLLS) has priced its previously announced $22M underwritten global offering by way of a capital increase of 8.8M American Depositary Shares at $2.50/ADS.Each ADS…
Cellectis (NASDAQ:CLLS), Primera Therapeutics to collaborate 2022/12/29 22:17:37 Seeking Alpha
Primera Therapeutics and French biotech Cellectis (CLLS) on Thursday said they would collaborate to develop therapies for mitochondrial diseases. Read more on the deal here.
Mayflower Bioventures Launches its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial Diseases 2022/12/29 21:30:00 GlobeNewswire
NEW YORK, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Following the formation of Mayflower Bioventures, a cell and gene therapy accelerator stood up from Hibiscus BioVentures and Mayo Clinic, comes the launch of their first start-up, Primera Therapeutics, Inc. (Primera). Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its gene editing platform to deliver life-saving cell and gene therapies, and Primera announced today the execution of a Collaboration Agreement under which the Parties will work collaboratively to edit mutations in the mitochondrial DNA (mtDNA) in vivo to treat the root cause of associated diseases.
Cellectis (NASDAQ:CLLS) to get €40M credit facility from European Investment Bank 2022/12/28 22:17:29 Seeking Alpha
Clinical-stage biotech Cellectis (CLLS) on Wednesday said it had entered into a €40M credit agreement with the European Investment Bank. Read more on the agreement here.
Cellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities 2022/12/28 21:30:00 GlobeNewswire
PARIS, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company“), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it has entered into a €40 million credit facility agreement with the European Investment Bank (“EIB”) (the “Finance Contract”).
Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL 2022/12/22 21:30:00 GlobeNewswire
NEW YORK, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that for the first time, a patient was dosed in the United States with its in-house manufactured product candidate UCART22, and completed the 28 day DLT period on December 14 th , 2022, without complication.
関連キーワード （バイオテクノロジ―_メディカルリサ―チ 米国株 セレクティス CLLS Cellectis S.A.）